{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T14:56:34Z","timestamp":1778424994850,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"32","license":[{"start":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T00:00:00Z","timestamp":1347235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T00:00:00Z","timestamp":1347235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2013,8,8]]},"DOI":"10.1038\/onc.2012.397","type":"journal-article","created":{"date-parts":[[2012,9,10]],"date-time":"2012-09-10T13:31:26Z","timestamp":1347283886000},"page":"3664-3675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Immunobiology of human mucin 1 in a preclinical ovarian tumor model"],"prefix":"10.1038","volume":"32","author":[{"given":"R A","family":"Budiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Elishaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Brozick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R P","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Kalinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Vlad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,10]]},"reference":[{"key":"BFonc2012397_CR1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.4161\/cc.8.5.7848","volume":"8","author":"W Shan","year":"2009","unstructured":"Shan W, Liu J . Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle 2009; 8: 731\u2013735.","journal-title":"Cell Cycle"},{"key":"BFonc2012397_CR2","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1038\/onc.2011.70","volume":"30","author":"LK Mullany","year":"2011","unstructured":"Mullany LK, Fan HY, Liu Z, White LD, Marshall A, Gunaratne P et al. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 2011; 30: 3522\u20133536.","journal-title":"Oncogene"},{"key":"BFonc2012397_CR3","first-page":"3459","volume":"63","author":"A Flesken-Nikitin","year":"2003","unstructured":"Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY . Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003; 63: 3459\u20133463.","journal-title":"Cancer Res"},{"key":"BFonc2012397_CR4","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMcibr051024","volume":"352","author":"J Boyd","year":"2005","unstructured":"Boyd J . Mouse models of gynecologic pathology. N Engl J Med 2005; 352: 2240\u20132242.","journal-title":"N Engl J Med"},{"key":"BFonc2012397_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nm0105-24","volume":"11","author":"MM Matzuk","year":"2005","unstructured":"Matzuk MM . Gynecologic diseases get their genes. Nat Med 2005; 11: 24\u201326.","journal-title":"Nat Med"},{"key":"BFonc2012397_CR6","first-page":"1389","volume":"63","author":"DC Connolly","year":"2003","unstructured":"Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63: 1389\u20131397.","journal-title":"Cancer Res"},{"key":"BFonc2012397_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2353\/ajpath.2006.060036","volume":"169","author":"DH Yang","year":"2006","unstructured":"Yang DH, Fazili Z, Smith ER, Cai KQ, Klein-Szanto A, Cohen C et al. Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background. The Am J Pathol 2006; 169: 258\u2013267.","journal-title":"The Am J Pathol"},{"key":"BFonc2012397_CR8","doi-asserted-by":"publisher","first-page":"e20715","DOI":"10.1371\/journal.pone.0020715","volume":"6","author":"PS Tanwar","year":"2011","unstructured":"Tanwar PS, Zhang L, Kaneko-Tarui T, Curley MD, Taketo MM, Rani P et al. Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt\/beta-Catenin and PTEN. PLoS One 2011; 6: e20715.","journal-title":"PLoS One"},{"key":"BFonc2012397_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nm1173","volume":"11","author":"DM Dinulescu","year":"2005","unstructured":"Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T . Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11: 63\u201370.","journal-title":"Nat Med"},{"key":"BFonc2012397_CR10","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1158\/0008-5472.CAN-08-3363","volume":"69","author":"HY Fan","year":"2009","unstructured":"Fan HY, Liu Z, Paquet M, Wang J, Lydon JP, DeMayo FJ et al. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res 2009; 69: 6463\u20136472.","journal-title":"Cancer Res"},{"key":"BFonc2012397_CR11","doi-asserted-by":"crossref","first-page":"15286","DOI":"10.1016\/S0021-9258(18)77254-2","volume":"265","author":"SJ Gendler","year":"1990","unstructured":"Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265: 15286\u201315293.","journal-title":"J Biol Chem"},{"key":"BFonc2012397_CR12","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.1073\/pnas.86.18.7159","volume":"86","author":"DL Barnd","year":"1989","unstructured":"Barnd DL, Lan MS, Metzgar RS, Finn OJ . Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86: 7159\u20137163.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2012397_CR13","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.4049\/jimmunol.151.7.3693","volume":"151","author":"CG Ioannides","year":"1993","unstructured":"Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ . Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993; 151: 3693\u20133703.","journal-title":"J Immunol"},{"key":"BFonc2012397_CR14","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.4049\/jimmunol.151.3.1654","volume":"151","author":"KR Jerome","year":"1993","unstructured":"Jerome KR, Domenech N, Finn OJ . Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993; 151: 1654\u20131662.","journal-title":"J Immunol"},{"key":"BFonc2012397_CR15","first-page":"2856","volume":"54","author":"Y Kotera","year":"1994","unstructured":"Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ . Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994; 54: 2856\u20132860.","journal-title":"Cancer Res"},{"key":"BFonc2012397_CR16","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1158\/0008-5472.CAN-09-0523","volume":"69","author":"R Ahmad","year":"2009","unstructured":"Ahmad R, Raina D, Joshi MD, Kawano T, Ren J, Kharbanda S et al. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res 2009; 69: 7013\u20137021.","journal-title":"Cancer Res"},{"key":"BFonc2012397_CR17","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/ncb1661","volume":"9","author":"R Ahmad","year":"2007","unstructured":"Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S et al. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nature Cell Biol 2007; 9: 1419\u20131427.","journal-title":"Nature Cell Biol"},{"key":"BFonc2012397_CR18","doi-asserted-by":"publisher","first-page":"7216","DOI":"10.1128\/MCB.18.12.7216","volume":"18","author":"Y Li","year":"1998","unstructured":"Li Y, Bharti A, Chen D, Gong J, Kufe D . Interaction of glycogen synthase kinase 3beta with the DF3\/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 1998; 18: 7216\u20137224.","journal-title":"Mol Cell Biol"},{"key":"BFonc2012397_CR19","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1074\/jbc.C000754200","volume":"276","author":"Y Li","year":"2001","unstructured":"Li Y, Kuwahara H, Ren J, Wen G, Kufe D . The c-Src tyrosine kinase regulates signaling of the human DF3\/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 2001; 276: 6061\u20136064.","journal-title":"J Biol Chem"},{"key":"BFonc2012397_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2005.01.008","volume":"7","author":"X Wei","year":"2005","unstructured":"Wei X, Xu H, Kufe D . Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005; 7: 167\u2013178.","journal-title":"Cancer Cell"},{"key":"BFonc2012397_CR21","doi-asserted-by":"publisher","first-page":"12492","DOI":"10.1074\/jbc.272.19.12492","volume":"272","author":"M Yamamoto","year":"1997","unstructured":"Yamamoto M, Bharti A, Li Y, Kufe D . Interaction of the DF3\/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 1997; 272: 12492\u201312494.","journal-title":"J Biol Chem"},{"key":"BFonc2012397_CR22","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1158\/0008-5472.CAN-10-4439","volume":"71","author":"DM Besmer","year":"2011","unstructured":"Besmer DM, Curry JM, Roy LD, Tinder TL, Sahraei M, Schettini J et al. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res 2011; 71: 4432\u20134442.","journal-title":"Cancer Res"},{"key":"BFonc2012397_CR23","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-03-0787","volume":"10","author":"GJ Rustin","year":"2004","unstructured":"Rustin GJ, Bast RC, Kelloff GJ, Barrett JC, Carter SK, Nisen PD et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clinical Cancer Res 2004; 10: 3919\u20133926.","journal-title":"Clinical Cancer Res"},{"key":"BFonc2012397_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2010.44","volume":"7","author":"AK Karam","year":"2010","unstructured":"Karam AK, Karlan BY . Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol 2010; 7: 335\u2013339.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFonc2012397_CR25","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.ejca.2011.07.004","volume":"48","author":"S Reinartz","year":"2011","unstructured":"Reinartz S, Failer S, Schuell T, Wagner U . CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. European J Cancer 2011; 48: 1558\u20131569.","journal-title":"European J Cancer"},{"key":"BFonc2012397_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ygyno.2011.02.020","volume":"121","author":"C Theriault","year":"2011","unstructured":"Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 2011; 121: 434\u2013443.","journal-title":"Gynecol Oncol"},{"key":"BFonc2012397_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1477-7827-2-4","volume":"2","author":"M Brayman","year":"2004","unstructured":"Brayman M, Thathiah A, Carson DD . MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol: RB&E 2004; 2: 4.","journal-title":"Reprod Biol Endocrinol: RB&E"},{"key":"BFonc2012397_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/jjco\/hyf111","volume":"32","author":"H Feng","year":"2002","unstructured":"Feng H, Ghazizadeh M, Konishi H, Araki T . Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 2002; 32: 525\u2013529.","journal-title":"Jpn J Clin Oncol"},{"key":"BFonc2012397_CR29","first-page":"641","volume":"53","author":"SB Ho","year":"1993","unstructured":"Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641\u2013651.","journal-title":"Cancer Res"},{"key":"BFonc2012397_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1309\/9R6673QEC06D86Y4","volume":"122","author":"SK Lau","year":"2004","unstructured":"Lau SK, Weiss LM, Chu PG . Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 2004; 122: 61\u201369.","journal-title":"Am J Clin Pathol"},{"key":"BFonc2012397_CR31","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1158\/1078-0432.CCR-03-0409","volume":"10","author":"KH Lu","year":"2004","unstructured":"Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10: 3291\u20133300.","journal-title":"Clin Cancer Res"},{"key":"BFonc2012397_CR32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2559.2010.03667.x","volume":"57","author":"CH Van Elssen","year":"2010","unstructured":"Van Elssen CH, Frings PW, Bot FJ, Van de Vijver KK, Huls MB, Meek B et al. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 2010; 57: 597\u2013606.","journal-title":"Histopathology"},{"key":"BFonc2012397_CR33","first-page":"315","volume":"58","author":"GJ Rowse","year":"1998","unstructured":"Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ . Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998; 58: 315\u2013321.","journal-title":"Cancer Res"},{"key":"BFonc2012397_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1242\/dmm.002535","volume":"2","author":"RA Budiu","year":"2009","unstructured":"Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM . A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Dis Mod Mech 2009; 2: 593\u2013603.","journal-title":"Dis Mod Mech"},{"key":"BFonc2012397_CR35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00262-011-1010-x","volume":"60","author":"RA Budiu","year":"2011","unstructured":"Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K et al. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 2011; 60: 975\u2013984.","journal-title":"Cancer Immunol Immunother"},{"key":"BFonc2012397_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","volume":"21","author":"KF Roby","year":"2000","unstructured":"Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21: 585\u2013591.","journal-title":"Carcinogenesis"},{"key":"BFonc2012397_CR37","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942\u2013949.","journal-title":"Nat Med"},{"key":"BFonc2012397_CR38","doi-asserted-by":"publisher","first-page":"8900","DOI":"10.1158\/0008-5472.CAN-07-1866","volume":"67","author":"I Kryczek","year":"2007","unstructured":"Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67: 8900\u20138905.","journal-title":"Cancer Res"},{"key":"BFonc2012397_CR39","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538\u201318543.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2012397_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1515\/BC.2009.070","volume":"390","author":"SO Ryan","year":"2009","unstructured":"Ryan SO, Vlad AM, Islam K, Gariepy J, Finn OJ . Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem 2009; 390: 611\u2013618.","journal-title":"Biol Chem"},{"key":"BFonc2012397_CR41","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00262-008-0648-5","volume":"58","author":"AS Giermasz","year":"2009","unstructured":"Giermasz AS, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W et al. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother 2009; 58: 1329\u20131336.","journal-title":"Cancer Immunol Immunother"},{"key":"BFonc2012397_CR42","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1084\/jem.20020493","volume":"196","author":"AM Vlad","year":"2002","unstructured":"Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L, Hanisch FG et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002; 196: 1435\u20131446.","journal-title":"J Exp Med"},{"key":"BFonc2012397_CR43","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323\u20135337.","journal-title":"Clin Cancer Res"},{"key":"BFonc2012397_CR44","doi-asserted-by":"crossref","first-page":"15099","DOI":"10.1016\/S0021-9258(18)98592-3","volume":"266","author":"AP Spicer","year":"1991","unstructured":"Spicer AP, Parry G, Patton S, Gendler SJ . Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J Biol Chem 1991; 266: 15099\u201315109.","journal-title":"J Biol Chem"},{"key":"BFonc2012397_CR45","doi-asserted-by":"publisher","first-page":"735","DOI":"10.4049\/jimmunol.179.2.735","volume":"179","author":"PL Beatty","year":"2007","unstructured":"Beatty PL, Plevy SE, Sepulveda AR, Finn OJ . Cutting edge: transgenic expression of human MUC1 in IL-10-\/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol 2007; 179: 735\u2013739.","journal-title":"J Immunol"},{"key":"BFonc2012397_CR46","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.4049\/jimmunol.181.5.3116","volume":"181","author":"TL Tinder","year":"2008","unstructured":"Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 2008; 181: 3116\u20133125.","journal-title":"J Immunol"},{"key":"BFonc2012397_CR47","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc2620","volume":"9","author":"K Polyak","year":"2009","unstructured":"Polyak K, Weinberg RA . Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265\u2013273.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2012397_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2009.09.017","volume":"291","author":"D Vergara","year":"2010","unstructured":"Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 2010; 291: 59\u201366.","journal-title":"Cancer Lett"},{"key":"BFonc2012397_CR49","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/onc.2010.526","volume":"30","author":"LD Roy","year":"2011","unstructured":"Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011; 30: 1449\u20131459.","journal-title":"Oncogene"},{"key":"BFonc2012397_CR50","doi-asserted-by":"publisher","first-page":"547179","DOI":"10.1155\/2010\/547179","volume":"2010","author":"P Allavena","year":"2010","unstructured":"Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol 2010; 2010: 547179.","journal-title":"Clin Dev Immunol"},{"key":"BFonc2012397_CR51","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/JCO.2009.27.2369","volume":"29","author":"LE Kandalaft","year":"2011","unstructured":"Kandalaft LE, Powell DJ, Singh N, Coukos G . Immunotherapy for ovarian cancer: what's next? J Clin Oncol 2011; 29: 925\u2013933.","journal-title":"J Clin Oncol"},{"key":"BFonc2012397_CR52","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.4049\/jimmunol.0902539","volume":"186","author":"K Palucka","year":"2011","unstructured":"Palucka K, Ueno H, Banchereau J . Recent developments in cancer vaccines. J Immunol 2011; 186: 1325\u20131331.","journal-title":"J Immunol"},{"key":"BFonc2012397_CR53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1600-0897.2007.00560.x","volume":"59","author":"K Odunsi","year":"2008","unstructured":"Odunsi K, Sabbatini P . Harnessing the immune system for ovarian cancer therapy. Am J Reprod Immunol 2008; 59: 62\u201374.","journal-title":"Am J Reprod Immunol"},{"key":"BFonc2012397_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1023\/A:1006332009414","volume":"60","author":"D Chen","year":"2000","unstructured":"Chen D, Koido S, Li Y, Gendler S, Gong J . T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice. Breast Cancer Res Treat 2000; 60: 107\u2013115.","journal-title":"Breast Cancer Res Treat"},{"key":"BFonc2012397_CR55","doi-asserted-by":"publisher","first-page":"6369","DOI":"10.1073\/pnas.94.12.6369","volume":"94","author":"C Wei","year":"1997","unstructured":"Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK et al. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci USA 1997; 94: 6369\u20136374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2012397_CR56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.immuni.2008.08.004","volume":"29","author":"CJ Melief","year":"2008","unstructured":"Melief CJ . Cancer immunotherapy by dendritic cells. Immunity 2008; 29: 372\u2013383.","journal-title":"Immunity"},{"key":"BFonc2012397_CR57","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","volume":"42","author":"RJ Kurman","year":"2011","unstructured":"Kurman RJ, Shih Ie M. . Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011; 42: 918\u2013931.","journal-title":"Hum Pathol"},{"key":"BFonc2012397_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1385\/IR:36:1:229","volume":"36","author":"AM Vlad","year":"2006","unstructured":"Vlad AM, Diaconu I, Gantt K . MUC1 in endometriosis and ovarian cancer. Immunol Res 2006; 36: 229\u2013236.","journal-title":"Immunol Res"},{"key":"BFonc2012397_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/gene.10036","volume":"32","author":"R Lesche","year":"2002","unstructured":"Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H et al. Cre\/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002; 32: 148\u2013149.","journal-title":"Genesis"},{"key":"BFonc2012397_CR60","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.4049\/jimmunol.165.7.3730","volume":"165","author":"EM Hiltbold","year":"2000","unstructured":"Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ . The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000; 165: 3730\u20133741.","journal-title":"J Immunol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2012397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2012397","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2012397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T17:05:56Z","timestamp":1687712756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2012397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,10]]},"references-count":60,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2013,8,8]]}},"alternative-id":["BFonc2012397"],"URL":"https:\/\/doi.org\/10.1038\/onc.2012.397","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,10]]},"assertion":[{"value":"22 December 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}